Compare Mesoblast Limited (MESO) vs Rocket Lab USA Inc (RKLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Rocket Lab USA Inc — how do they compare? Mesoblast Limited trades at $16.23 (market cap $2.17B), while Rocket Lab USA Inc trades at $69.13 (market cap $41.08B). The key difference: Rocket Lab USA Inc is far larger — about 18.9× Mesoblast Limited's market cap, and Mesoblast Limited is trading nearer its 52-week high, Rocket Lab USA Inc nearer its low. Which is the better fit depends on your goals.
| MESO | RKLB | |
|---|---|---|
Market Cap | $2.17B | $41.08B |
Sector | Technology | Technology |
52-Week High | $20.96 | $150.23 |
52-Week Low | $12.88 | $39.48 |
Enterprise Value | $2.17B | $39.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Rocket Lab (RKLB) trades at $65.74, down 2.78% on the day, reflecting a bearish technical trend with support at $63. The company shows strong revenue growth with $601.80M in 2025 but remains unprofitable with a net loss of $198.21M. Recent news highlights competition with SpaceX and a potential catalyst from the Neutron rocket's development. Analyst consensus is overwhelmingly bullish with a $116.90 price target, though technical indicators signal near-term caution.
The outlook for RKLB hinges on execution of its growth strategy and path to profitability. Investment opportunity lies in its expanding launch contracts and competitive positioning in the space sector. Key risks include persistent cash burn, intense competition, and reliance on successful Neutron launches. Investors should weigh strong analyst optimism against fundamental challenges and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →
